AR115666A1 - Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo - Google Patents
Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitriloInfo
- Publication number
- AR115666A1 AR115666A1 ARP190101846A ARP190101846A AR115666A1 AR 115666 A1 AR115666 A1 AR 115666A1 AR P190101846 A ARP190101846 A AR P190101846A AR P190101846 A ARP190101846 A AR P190101846A AR 115666 A1 AR115666 A1 AR 115666A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihydropyridazin
- carbonitrile
- dioxo
- tetrahydro
- dichloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692914P | 2018-07-02 | 2018-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115666A1 true AR115666A1 (es) | 2021-02-10 |
Family
ID=67441642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101846A AR115666A1 (es) | 2018-07-02 | 2019-07-01 | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210122740A1 (enExample) |
| EP (2) | EP4552643A3 (enExample) |
| JP (2) | JP2021530456A (enExample) |
| KR (2) | KR20250167140A (enExample) |
| CN (1) | CN112638904A (enExample) |
| AR (1) | AR115666A1 (enExample) |
| AU (2) | AU2019298236A1 (enExample) |
| CA (1) | CA3104860A1 (enExample) |
| IL (2) | IL321116A (enExample) |
| MX (3) | MX2021000107A (enExample) |
| TW (1) | TW202019914A (enExample) |
| WO (1) | WO2020010068A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| CN110167557A (zh) | 2016-10-18 | 2019-08-23 | 马德里加尔制药公司 | 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法 |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| SI3965884T1 (sl) | 2019-05-08 | 2025-05-30 | Aligos Therapeutics, Inc. | Modulatorji thr-beta z glavno skupino dioxo-1,2,4-triazil |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN114787153A (zh) * | 2019-12-26 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CA3192243A1 (en) | 2020-09-10 | 2022-03-17 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of resmetirom, preparation method therefor, and use thereof |
| US20230364099A1 (en) | 2020-10-19 | 2023-11-16 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| JP2024506848A (ja) * | 2021-02-01 | 2024-02-15 | マドリガル ファーマシューティカルズ インコーポレイテッド | 肝障害又は脂質障害の治療のためのロスバスタチンとレスメチロムの治療的組み合わせ |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| US20240218009A1 (en) * | 2021-04-21 | 2024-07-04 | Merck Sharp & Dohme Llc | Novel forms of cyclic dinucleotide compounds |
| IL312637A (en) * | 2021-11-11 | 2024-07-01 | Terns Pharmaceuticals Inc | Treatment of liver disorders with a thr-β agonist |
| US20240423992A1 (en) | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | Biomarkers for treating liver disorders with thr-b agonists and related uses |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025172958A1 (en) * | 2024-02-16 | 2025-08-21 | Metrochem Api Pvt Ltd | Solid state forms of resmetirom |
| WO2025231587A1 (zh) * | 2024-05-06 | 2025-11-13 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗无水晶型ch及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| RU2379295C2 (ru) * | 2005-07-21 | 2010-01-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона |
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| CN110167557A (zh) * | 2016-10-18 | 2019-08-23 | 马德里加尔制药公司 | 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法 |
-
2019
- 2019-07-01 TW TW108123112A patent/TW202019914A/zh unknown
- 2019-07-01 AR ARP190101846A patent/AR115666A1/es unknown
- 2019-07-02 KR KR1020257038532A patent/KR20250167140A/ko active Pending
- 2019-07-02 CN CN201980056826.0A patent/CN112638904A/zh active Pending
- 2019-07-02 EP EP24214548.0A patent/EP4552643A3/en active Pending
- 2019-07-02 AU AU2019298236A patent/AU2019298236A1/en not_active Abandoned
- 2019-07-02 MX MX2021000107A patent/MX2021000107A/es unknown
- 2019-07-02 JP JP2020572517A patent/JP2021530456A/ja active Pending
- 2019-07-02 KR KR1020217003360A patent/KR102890565B1/ko active Active
- 2019-07-02 US US17/257,070 patent/US20210122740A1/en not_active Abandoned
- 2019-07-02 IL IL321116A patent/IL321116A/en unknown
- 2019-07-02 WO PCT/US2019/040276 patent/WO2020010068A1/en not_active Ceased
- 2019-07-02 EP EP19745399.6A patent/EP3818057A1/en not_active Withdrawn
- 2019-07-02 CA CA3104860A patent/CA3104860A1/en active Pending
-
2020
- 2020-12-23 IL IL279700A patent/IL279700A/en unknown
-
2021
- 2021-01-06 MX MX2023009701A patent/MX2023009701A/es unknown
- 2021-01-06 MX MX2024013198A patent/MX2024013198A/es unknown
-
2024
- 2024-05-09 JP JP2024076310A patent/JP2024105460A/ja active Pending
- 2024-11-15 US US18/949,309 patent/US20250074898A1/en active Pending
-
2025
- 2025-01-10 AU AU2025200189A patent/AU2025200189A1/en active Pending
- 2025-08-19 US US19/303,585 patent/US20250368626A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019298236A1 (en) | 2021-01-21 |
| KR102890565B1 (ko) | 2025-11-24 |
| US20210122740A1 (en) | 2021-04-29 |
| WO2020010068A1 (en) | 2020-01-09 |
| CN112638904A (zh) | 2021-04-09 |
| CA3104860A1 (en) | 2020-01-09 |
| MX2024013198A (es) | 2024-12-06 |
| IL321116A (en) | 2025-07-01 |
| MX2021000107A (es) | 2021-05-27 |
| EP3818057A1 (en) | 2021-05-12 |
| EP4552643A3 (en) | 2025-07-02 |
| MX2023009701A (es) | 2023-08-29 |
| US20250368626A1 (en) | 2025-12-04 |
| IL279700A (en) | 2021-03-01 |
| KR20250167140A (ko) | 2025-11-28 |
| US20250074898A1 (en) | 2025-03-06 |
| JP2021530456A (ja) | 2021-11-11 |
| TW202019914A (zh) | 2020-06-01 |
| AU2025200189A1 (en) | 2025-01-30 |
| JP2024105460A (ja) | 2024-08-06 |
| EP4552643A2 (en) | 2025-05-14 |
| KR20210027454A (ko) | 2021-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115666A1 (es) | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo | |
| CO2019003709A2 (es) | Conjugados de pirrolobenzodiazepina | |
| CU20200014A7 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| MX2018012287A (es) | Metodos de tratamiento para enfermedades colestasicas y fibroticas. | |
| ECSP21081726A (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| MX362339B (es) | Forma de sal de un inhibidor de histona metiltransferasa humana ezh2. | |
| AR101994A1 (es) | COMPUESTOS DE PIRROLIDINA ANTAGONISTAS DE INTEGRINA avb6 | |
| PE20152032A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il | |
| UY37517A (es) | Métodos de síntesis de compuestos tiazoles sustituidos | |
| FR2974189B1 (fr) | Systeme d'imagerie comprenant une lentille de fresnel | |
| CO2022004589A2 (es) | Uso de un agonista del receptor de orexina 2 para el tratamiento de la somnolencia excesiva | |
| CL2017001164A1 (es) | Compuesto de diaril isoxazolina | |
| CL2021000797A1 (es) | Una ayuda para la deposición de fluidos agrícolas. | |
| AR104935A1 (es) | Formas cristalinas de un inhibidor de histona deacetilasa | |
| EA202192453A1 (ru) | Полиморфы и сокристаллы активатора кардиотропонина | |
| MX2018007414A (es) | Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f¬]isoqui nolin-2-amina sustituidos. | |
| ECSP22046595A (es) | Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina | |
| EA202190694A1 (ru) | Композиция поверхностно-активных веществ и ее применение | |
| MX2021009423A (es) | Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). | |
| EA202190695A1 (ru) | Композиция поверхностно-активных веществ и ее применение | |
| CL2017001899A1 (es) | Sal de tosilato | |
| IL290446A (en) | Intraocular lens with extended depth of focus | |
| MX2020008066A (es) | Formas de sal de compuesto organico. | |
| UA40189S (uk) | Тарілка закусочна «синій оксамит» | |
| HK40042835A (en) | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |